Video
Dr. Zhang on risk stratification and treatment selection in mCSPC
Author(s):
Video Player is loading.
Jingsong Zhang, MD, PhD, discusses contributing factors to risk stratification and subsequent treatment selection in patients with metastatic castration-sensitive prostate cancer. The factors Zhang highlights include site of metastases, PSA response, and metastases burden.
Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
Selecting Between Receptor Pathway Inhibitors for mHSPC
The Use of Ultra-Low PSA in Specific Patient Profiles
Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
Related Content
